1. In Vivo
  2. >>Leadership
  3. >>C-Suite Speaks

Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy

 
• By Jo Shorthouse

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

Lung Cancer

The lung cancer therapeutic space is fast-paced and hopeful, with new therapies approved for gene mutations allowing for personalized medicine and an evolving understanding of disease biology. And dynamic it must be, with lung cancer the most commonly occurring cancer worldwide, accounting for 12.4% of total new cases.

AstraZeneca’s Stable Of Lung Cancer Therapies

  • Tagrisso (osimertinib)

  • Iressa (gefitinib)

  • Imfinzi (durvalumab)

  • Imjudo (tremelimumab)

In March, the FDA approved Johnson & Johnson’s Rybrevant (mivantamab) with chemotherapies carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

More from Leadership

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By David Wild

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.